Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMINARY: SAGE-718 in MCI or Mild Dementia Due to Alzheimer's Disease
NCT04602624Phase 2Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalzanemdor in Alzheimer's disease (AD), sponsored by Supernus Pharmaceuticals, Inc. Primary endpoint: Treatment-Emergent Adverse Events up to 28 days. Started Dec 2020; status: completed.
02
Drugs
dalzanemdor
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04602624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602624.